Evan Lockwood Rachlin, an insider at Iambic Therapeutics, Inc. (IAM), executed a significant purchase of company stock on October 19, 2026. Rachlin acquired 718,750 shares at a price of $16.00 per share, representing a total investment of approximately $11.50 million.
This substantial acquisition by an insider is often interpreted as a strong signal of confidence in the company's future performance.
The purchase adds to recent insider activity, with Rachlin previously engaging in a buy transaction of similar magnitude. Such large-scale insider buying can draw investor attention, especially within the biotechnology sector where company-specific developments often drive significant stock movements.